

Electronic Annex 6: Interval between drug administration and adverse event occurrence, according to the treatment outcome at the study data collection.

	Still on treatment	Other outcomes	Total
	Median (IQR) interval between first drug administration and AEs, days		
Linezolid	71 (32-139)	115 (52-191)	93.5 (40-169)
Bedaquiline	71 (28-160)	94 (30-184)	90 (30-177)
Capreomycin	57 (32-62)	75 (34-176)	62 (32.5-150.0)
Pyrazinamide	61 (30-105)	69 (33-178)	62 (31-116)
Ethionamide/prothionamide	162.5 (48.5-235.5)	159.5 (25-305)	159.5 (30.5-281.5)
Amikacin	81.5 (46.5-94.5)	61 (45-109)	80 (45-106)
Cycloserine/terizidone	105 (55-291)	93.5 (43-153)	105 (44-215)
Para-aminosalicylic acid	114 (32.5-206.0)	258 (70-629)	216 (93-603)
Delamanid	121.5 (59-181)	76 (22.5-100.5)	77 (24-179)
Levofloxacin	57 (53-103)	17 (7-160)	57 (12-160)
Clofazimine	132 (130-132)	97 (83-161)	131 (83-161)
Moxifloxacin	70.5 (22.5-118.5)	119.5 (52-254)	88 (34-170)
Clarithromycin	-	-	-
Mean (SD) total duration, days	92 (34.3)	102.9 (60.1)	79.5 (42.4)

Legend: IQR: interquartile range; AE: adverse event; PAS: Para-aminosalicylic acid; SD: standard deviation